News Focus
News Focus
icon url

eagle8

10/14/22 11:23 AM

#521860 RE: biosectinvestor #521857

I think if the world knows what DCvax can do, they DEMAND to use it for other tumors as well.
The world will soon know that the MOA is the same (L and Direct).
So applicable to almost ALL tumors.

GLTU
icon url

dennisdave

10/15/22 7:36 AM

#522066 RE: biosectinvestor #521857

These guys are, I am pretty sure, trying to not just demonstrate efficacy for gbm, but with biomarkers, for tumors generally.



If that's the case they should change the study description on the government website https://clinicaltrials.gov/ct2/show/NCT00045968


Study Description
Brief Summary:
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.

is Phase III trial is designed to evaluate the impact on survival time, as well as safety, in patients following treatment with DCVax(R)-L, an immunotherapy treatment for GBM.